In Japan, this drug is approved for treatment of patients with different T cell malignancies such as relapsed/refractory (R/R) CCR4+ ATL and cutaneous T-cell lymphoma (CTCL) (Ishii et al., 2010). This evidence concerns the gene CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma.